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10.3 m, P= 0.14). Response rate was 32.7% and 38.7% in women and 
men, respectively (P=0.4).
Conclusions: Based on this study the MOS was not statistically sig-
niﬁcant between women and men with advanced NSCLC treated with 
platinum based chemotherapy. Differences in pathologic subtype and 
mean age may translate this ﬁnding. To elucidate the impact of sex on 
MOS in patients with advanced NSCLC we need further well balanced 
studies. 
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Background: Docetaxel is a taxene anticancer drug with activity 
against a broad range of cancers. Pulmonary toxicity is a well-known 
complication observed with several anticancer drugs. But, interstitial 
pneumonitis as a toxicity of docetaxel is very rare.
Methods: A total of 53 patients with non-small cell lung cancer who 
received chemotherapy including docetaxel from January 2006 to 
December 2006 were analyzed retrospectively. 
Results: 9 out of 53 patients (17.0%) showed newly developed ground 
glass opacity with/without consolidation or reticular density on fol-
low up chest CT scans during docetaxel therapy. The lesions were 
not thought to be associated with disease progression or pulmonary 
infection. Majority of patients who showed newly developed abnormal 
CT ﬁndings consistent with interstitial pneumonitis had worsened or 
newly appeared dyspnea with deterioration of lung function of restric-
tive pattern. In association with the chemotherapy regimens, 7 out of 
9 patients with DIIP received weekly docetaxel (30-40mg/m2), and 
remaining 2 received non-weekly docetaxel(60-75mg/m2). Among 7 
patients who received weekly docetaxel, docetaxel only (30mg/m2) 
were 4, and docetaxel (40mg/m2) combined with cisplatin(35mg/m2) 
were 3. In association with the cumulative dose of docetaxel, below 
60mg/m2 was none, between 60 and 120 mg/m2 was 1, between 120 
and 240 mg/m2 were 4, and between 240 and 480mg/m2 were 4. The 
locations of abnormal radiographic ﬁndings were mainly peripheral (8 
out of 9) and upper lobe (7 out of 9). For the treatment of DIIP 4 out of 
9 patients received corticosteroid treatment, and all 4 patients showed 
symptomatic improvement. 
Conclusions: DIIP developed in increasing frequency as the cumula-
tive dose of docetaxel increased, especially with weekly regimen. 
Special concern should be given to the development of DIIP during 
docetaxel chemotherapy as its cumulative dose increases. DIIP should 
be included in differential diagnosis of newly developed radiographic 
abnormalities such as ground glass opacity or consolidation during 
docetaxel treatment especially if the lesion is peripheral and upper lobe 
predominant. For more clear clariﬁcation of DIIP, further prospective 
study of large scale is required.
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Background: To evaluate the efﬁcacy and safety of induction chemo-
therapy with docetaxel and carboplatin in advanced lung cancer.
Methods: Between January 2005 and January 2007, 54 patients were 
enrolled and evaluable. Patients were treated with Docetaxel 75mg/m3 
and Carboplatin AUC 5 on day 1 every 21 days.
Result: The median age was 62 (range 23-79) years old. Among the 
54 patients, 51 were male. Pathologically, 19 patients had adenocar-
cinoma, 19 patients had squamous carcinoma and 3 patients had large 
cell carcinoma. Complete responses (CR) were in 2(3.7%) patients and 
partial responses (PR) in 26(48.14%) patients. The overall response 
rate was 51.85% and the median response duration was 5 (range, 1 to 
12.7) months. The median progression-free survival was 10.5 (range, 
1.4 to 19.5) months. The median overall survival for all patients was 
14.8 (range, 1.4 to 23.8) months.
During a total 253 cycles, anemia greater than CTC grade 2 occurred 
in 51 cycles(20.15%), leukopenia occurred in 22 cycles(8.69%) and 
thrombocytopenia occurred in 19 cycles(7.5%). Non-hematologic 
toxicities were minor and easily controlled.
Conclusion: The combination chemotherapy of docetaxel and carbo-
platin has moderate efﬁcacy with acceptable toxicities in patients with 
advanced NSCLC.
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Background: We conducted retrospective analysis to evaluate the efﬁ-
cacy and characteristics of palliative chemotherapy for elderly patients 
with advanced or recurrent non-small cell lung cancer(NSCLC).
Methods: Between Mar 2000 and Feb 2004, newly diagnosed chemo-
naïve patients with advanced or recurrent NSCLC were included. All 
patients were histologically or pathologically proven to be NSCLC, 
with performance status 0 to 2. Comorbidity was evaluated according 
to the Charlson’s comorbidity index. All patients received platinum-
based combination chemotherapy(containing paclitaxel or gemcitabine) 
as the ﬁrst-line treatment. The old age group was deﬁned as patients 
with 65 years or more of age.
Results: Total 404 patients were retrospectively analyzed. The number 
of patients in the young age and the old age group were 283(70%) and 
121(30%), respectively. The average number of total regimens(2.31 of 
old age vs. 2.81 of young age, respectively;p<0.001) and cycles(8.78 
vs. 10.69, p=0.006) per head were signiﬁcantly less in the old age 
group than in the young age group. Average administered doses of 
paclitaxel(119.3 vs. 137.4 mg/m2, p<0.001) and gemcitabine(1962.1 vs. 
2216.7 mg/m2, p<0.001) per cycle were lower in the old age group than 
